CG Oncology (CGON) reported Friday initial results from a phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk, non-muscle invasive bladder cancer.

The biopharmaceutical company said the data "demonstrate encouraging high-grade event-free survival, high complete response rates, and a well-tolerated safety profile."

CG Oncology will present the data Saturday at the 2026 American Urological Association annual meeting in Washington, DC.

"As the first prospective intravesical-only combination study of its kind, these early data demonstrate robust clinical activity across both treatment schedules, a favorable safety profile, and comparable efficacy," Chief Medical Officer Vijay Kasturi said in a statement.